Dogwood Therapeutics Announces Low Dose IMC-2 Reduces Long-COVID Related Fatigue and Sleep Disturbance
Dogwood Therapeutics, Inc, a development-stage biotechnology company advancing new medicines to treat pain and fatigue-related disorders, announced top line data from the recently completed BHC IMC-2 Long-COVID study. The...